• Home
  • Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib.

Author List
Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E
Publication
Blood advances
Publication ID (Profile URL)
https://researcherprofiles.org/profile/263461592
Publication Year
2022
PubMed ID
35130342
Publication Title
Smith CC, Levis MJ, Perl AE, Hill JE, Rosales M, Bahceci E. Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib. Blood Adv. 2022 04 12; 6(7):2144-2155.